Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casirivimab+Imdevimab in high-risk pediatric subjects under 12 years
NCT04992273Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of casirivimab + imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Started Sep 2021; status: terminated.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04992273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992273.